Compare · HAE vs MDLN
HAE vs MDLN
Side-by-side comparison of Haemonetics Corporation (HAE) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HAE and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.61B, about 10.1x HAE ($4.63B).
- Both names hit the wire about 4 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- Haemonetics Corporation
- Medline Inc.
- Price
- -
- -
- Market cap
- $4.63B
- $46.61B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1991
- 2025
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 25
Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Latest HAE
- SEC Form 8-K filed by Haemonetics Corporation
- Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
- Haemonetics upgraded by Citigroup with a new price target
- Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
- AZENTA ANNOUNCES LEADERSHIP TRANSITION
- Haemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form S-8 filed by Haemonetics Corporation
- SEC Form 10-Q filed by Haemonetics Corporation
- Haemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Latest MDLN
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)